Deals

Adlai Nortye Strikes Cetuximab Supply Deals with Eli Lilly and Merck KGaA – Backing Global Phase 1 Trial of First‑in‑Class CEACAM5 ADC AN4035
ADC / XDCAdlai Nortye

Adlai Nortye Strikes Cetuximab Supply Deals with Eli Lilly and Merck KGaA – Backing Global Phase 1 Trial of First‑in‑Class CEACAM5 ADC AN4035

Adlai Nortye (NASDAQ: ANL) announced that it has separately entered into clinical trial collaboration and drug supply agreements with Eli Lilly and Company (NYSE: LLY) and Merck KGaA, Darmstadt, Germany…

Harbin Gloria Pharmaceuticals Acquires Capital Medical University Patent for RMB 11.15 Million – Backing First‑in‑Class TLK2 Gene Therapy for Glaucoma Neuroprotection

Harbin Gloria Pharmaceuticals Acquires Capital Medical University Patent for RMB 11.15 Million – Backing First‑in‑Class TLK2 Gene Therapy for Glaucoma Neuroprotection

insitro Signs Worldwide Exclusive Research Deal with AstraZeneca – Up to USD 1.5 Billion to Apply Virtual Human Platform in MASH and Cardiomyopathies

insitro Signs Worldwide Exclusive Research Deal with AstraZeneca – Up to USD 1.5 Billion to Apply Virtual Human Platform in MASH and Cardiomyopathies

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
NVIDIA and Novo Nordisk Collaborate to Accelerate AI-Driven Drug Discovery
AINASDAQ: NVDA

NVIDIA and Novo Nordisk Collaborate to Accelerate AI-Driven Drug Discovery

Bayer Extends Genomics Partnership With Broad Institute for Cardiology Research
BayerCVD

Bayer Extends Genomics Partnership With Broad Institute for Cardiology Research

Bayzed Health Launches HK IPO to Expand Cancer Care Services
Bayzed HealthCancer

Bayzed Health Launches HK IPO to Expand Cancer Care Services

TransThera Sciences Sets Hong Kong IPO at HKD13.15 Per Share
CancerIPO

TransThera Sciences Sets Hong Kong IPO at HKD13.15 Per Share

Show More